Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Diseases 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Sorafenib 42Bevacizumab 26Oxaliplatin 21Radiosurgery 19Gemcitabine 17Fluorouracil 15Hepatectomy 13lenvatinib 12Radiofrequency Ablation 11Nivolumab 11Cisplatin 11Radiotherapy 10Doxorubicin 10Capecitabine 10durvalumab 9Leucovorin 9Blood Specimen Collection 9atezolizumab 8Liver Transplantation 8Everolimus 7Electroporation 7pembrolizumab 6camrelizumab 6Sunitinib 6Immunohistochemistry 6Cryosurgery 6Carboplatin 6tremelimumab 5sintilimab 5apatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Liver Neoplasms × bavituximab × Clear all
NCT01264705 2020-11-12

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Completed
47 enrolled 10 charts
Gastrointestinal

Fibrosis, Gastrointestinal Neoplasms, Hepatitis, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡